A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of TOL-3021 in Patients With New Onset or Established Type 1 Diabetes Mellitus
Latest Information Update: 17 Sep 2021
At a glance
- Drugs TOL 3021 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SUNRISE
- Sponsors Tolerion
Most Recent Events
- 05 Nov 2020 Status changed from recruiting to active, no longer recruiting.
- 14 Oct 2020 Planned End Date changed from 14 Aug 2023 to 30 Sep 2023.
- 14 Oct 2020 Planned primary completion date changed from 14 Aug 2021 to 15 Mar 2021.